27F0 Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. More details

27F0 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 20.8% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the German market

Earnings are forecast to decline by an average of 11.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

KALA BIO, Inc. Competitors

4SC

DB:VSC

€61.5m

Medigene

XTRA:MDG1

€22.8m

Heidelberg Pharma

XTRA:HPHA

€106.3m

2invest

XTRA:2INV

€67.8m

Price History & Performance

Summary of share price highs, lows and changes for KALA BIO
Historical stock prices
Current Share Price	US$7.85
52 Week High	US$10.85
52 Week Low	US$4.22
Beta	-2.04
1 Month Change	13.45%
3 Month Change	23.93%
1 Year Change	20.69%
3 Year Change	-74.96%
5 Year Change	-97.36%
Change since IPO	-99.04%

Recent updates

Shareholder Returns

	27F0	DE Biotechs	DE Market
7D	-27.7%	-3.2%	2.7%
1Y	20.7%	-7.9%	17.0%

Return vs Industry: 27F0 exceeded the German Biotechs industry which returned -7.9% over the past year.

Return vs Market: 27F0 exceeded the German Market which returned 17% over the past year.

Price Volatility

Is 27F0's price volatile compared to industry and market?
27F0 volatility
27F0 Average Weekly Movement	16.1%
Biotechs Industry Average Movement	5.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 27F0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 27F0's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2009	43	Todd Bazemore	www.kalarx.com

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

KALA BIO, Inc. Fundamentals Summary

How do KALA BIO's earnings and revenue compare to its market cap?
27F0 fundamental statistics
Market cap	€48.65m
Earnings (TTM)	-€37.13m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Is 27F0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
27F0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$38.96m
Earnings	-US$38.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-6.40
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	512.3%

How did 27F0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/16 03:30
End of Day Share Price	2025/02/14 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Yi Chen	H.C. Wainwright & Co.
Raghuram Selvaraju	H.C. Wainwright & Co.

27F0 Stock Overview

Rewards

Risk Analysis

KALA BIO, Inc. Competitors

DB:VSC

€61.5m

XTRA:MDG1

€22.8m

XTRA:HPHA

€106.3m

XTRA:2INV

€67.8m

Price History & Performance

Recent News & Updates

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New minor risk - Share price stability

New major risk - Shareholder dilution

Recent updates

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New minor risk - Share price stability

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Third quarter 2022 earnings released: EPS: US$19.40 (vs US$21.62 loss in 3Q 2021)

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Insufficient new directors

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

Revenue misses expectations

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Shareholder Returns

Price Volatility

About the Company

KALA BIO, Inc. Fundamentals Summary

0.0x

-1.3x

Earnings & Revenue

Company Analysis and Financial Data Status